Potential of Splicing Factor as a Target for Preeclampsia Treatment
Recent research uncovers the role of the splicing factor SRSF5 in preeclampsia development, offering promising new targets for therapy to improve maternal and fetal health outcomes.
Preeclampsia is a serious pregnancy complication characterized by high blood pressure, organ damage, and inadequate blood flow to the fetus. The only definitive cure currently is delivery, but early intervention remains a challenge. Recent research exploring the molecular mechanisms behind preeclampsia has identified a promising target: the splicing factor SRSF5.
A study published in The FASEB Journal investigated the role of SRSF5 in the development of preeclampsia. Using bioinformatics and experimental models, researchers observed that SRSF5 was significantly upregulated in placental tissues from women with preeclampsia. Elevated SRSF5 affects the alternative splicing of the pre-mRNA of MLX, a transcription factor, resulting in a longer, more stable form of MLX. This abnormal MLX interacts with NR2F2, a critical regulator in placental vascular and immune functions, suppressing its activity and leading to placental cell death.
In vivo tests on a mouse model demonstrated that high levels of SRSF5 correlated with preeclampsia-like symptoms, including high blood pressure and proteinuria. Conversely, reducing SRSF5 levels improved placental function and lowered maternal blood pressure. These findings suggest that SRSF5 plays a pivotal role in preeclampsia pathogenesis.
The implications of this research are significant, as targeting SRSF5 or the splicing process could open new therapeutic avenues. Unlike current treatments that only mitigate symptoms, drugs designed to modulate SRSF5 activity may address the root causes of preeclampsia, improving outcomes for mothers and their babies.
This groundbreaking study highlights the importance of molecular research in understanding complex pregnancy disorders and paves the way for potential targeted therapies in the future.
Source: https://medicalxpress.com/news/2025-10-splicing-factor-therapeutic-preeclampsia.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Targeting the Cerebellum to Alleviate Alcohol Withdrawal Symptoms: New Research Findings
New research from Washington State University suggests that targeting the cerebellum, a brain region traditionally associated with movement, could significantly reduce symptoms of alcohol withdrawal, paving the way for targeted therapies for alcohol use disorder.
Preoperative Palliative Care Needs Lead to Higher Post-Surgery Healthcare Utilization in Older Adults with Serious Illness
Older adults with serious preoperative illnesses have significantly higher healthcare utilization and costs after elective surgery, highlighting the need for integrated palliative care strategies to improve outcomes.
How Immune Cells Use 'Mini-Hulk' Mechanics to Navigate Tight Spaces in Tissues
A groundbreaking study uncovers how immune cells, dubbed 'mini-Hulks', generate forces to push through tissues, ensuring effective immune surveillance and response. This mechanism involves a central actin structure that helps dendritic cells navigate tight spaces safely, with implications for understanding immune deficiencies.
